Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiophanate SCHEMBL29398343 | 0.91 | ALDH1A1 (0.70) | ALDH1A1MAPTHPGDLMNAALOX15 | |
| Thiophanate SCHEMBL20842 | 0.91 | ALDH1A1 (0.70) | ALDH1A1MAPTHPGDLMNAALOX15 | |
| Thiophanate SCHEMBL7449541 | 0.89 | ALDH1A1 (0.68) | ALDH1A1MAPTHPGDLMNAALOX15 | |
| SCHEMBL12336304 | 0.87 | ALDH1A1 (0.64) | ALDH1A1MAPTHPGDLMNAALOX15 | |
| SCHEMBL11694452 | 0.87 | ALDH1A1 (0.79) | ALDH1A1MAPTHPGDLMNAALOX15 | |
| SCHEMBL23727265 | 0.87 | EPHX1 (0.65) | ALDH1A1MAPTGAAHPGDLMNA | |
| Thiophanate SCHEMBL10922494 | 0.87 | ALDH1A1 (0.79) | ALDH1A1MAPTHPGDLMNAALOX15 | |
| SCHEMBL11793473 | 0.85 | ALDH1A1 (0.62) | ALDH1A1MAPTHPGDLMNAALOX15 | |
| SCHEMBL11834021 | 0.85 | ALDH1A1 (0.71) | ALDH1A1MAPTHPGDLMNAALOX15 | |
| SCHEMBL11835690 | 0.85 | ALDH1A1 (0.62) | ALDH1A1MAPTHPGDLMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343726-A1 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | THE ROCKEFELLER UNIVERSITY (US) | 2024-10-17 | — | — | US | disclosed |
| WO-2023015156-A1 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | HUDSPETH A JAMES (US) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343726-A1 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | LATS1, LATS2, YAP1 | ALDH1A1 3828/4885MAPT 3089/4885GAA 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.